HUMA News & Events

Humacyte announced that its Marketing Authorization Application, MAA, seeking approval of the acellular tissue engineered vessel for arterial trauma repair has been accepted by the Israel Ministry of Health. The Ministry of Health has set a 180-working-day review period for the MAA due to the existing Food and Drug Administration, FDA, approval of Symvess in extremity vascular trauma. "We are very pleased that the Ministry of Health has accepted our MAA filing and has granted a 180-day review period," said Laura Niklason, M.D., Ph.D., Founder and Chief Executive Officer of Humacyte. "The MAA acceptance us another step in our planned global expansion of Symvess as we seek to provide this innovative regenerative medicine product to patients throughout the world. Many patients with severe vascular injuries are underserved by the current standard of care, and we are proud of the results that have been seen in our clinical trials and real-world humanitarian efforts.".

Latest data shows the largest indicative borrow rate increases among liquid option names include: Humacyte (HUMA) 16.96% +1.30, Infosys (INFY) 14.10% +1.29, Defiance 1.75x MSTR ETF (MSTX) 27.68% +1.03, Yellowstone Midco Holdings Ii, Llc (YSS) 5.98% +0.78, Mesoblast (MESO) 9.20% +0.53, Navient (NAVI) 0.94% +0.53, Equinor (EQNR) 1.81% +0.51, Rumble (RUM) 7.11% +0.49, Lucid Group (LCID) 27.88% +0.35, and Palladyne AI Corp (PDYN) 16.25% +0.33.

Latest data shows the largest indicative borrow rate increases among liquid option names include: Humacyte (HUMA) 19.23% +1.16, DeFi Development Corp (DFDV) 23.71% +0.78, Defiance Daily Target 2X Long HIMS ETF (HIMZ) 28.05% +0.67, ASP Isotopes Inc (ASPI) 1.97% +0.44, Vodafone (VOD) 9.09% +0.39, Recursion Pharmaceuticals (RXRX) 2.55% +0.35, DEFIANCE DAILY TARGET 2X LONG RIOT ETF (RIOX) 25.64% +0.32, Faraday Future Intelligent Electric Inc (FFAI) 11.15% +0.31, Vistra Energy (VST) 0.46% +0.21, and Bit Digital (BTBT) 0.66% +0.18.